The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
Open accessAbstract
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the treatment of homologous recombination (HR)-deficient cancers. Despite the success of this approach, drug resistance is a clinical hurdle, and we poorly understand how cancer cells escape the deadly effects of PARPi without restoring the HR pathway. By combining genetic screens with multi-omics analysis of matched PARPi-sensitive and -resistant Brca2-mutated mouse mammary tumors, we identified loss of PAR glycohydrolase (PARG) as a major resistance mechanism. We also found the presence of PARG-negative clones in a subset of human serous ovarian and triple-negative breast cancers. PARG depletion restores PAR formation and partially rescues PARP1 signaling. Importantly, PARG inactivation exposes vulnerabilities that can be exploited therapeutically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
MultiQC: summarize analysis results for multiple tools and samples in a single report
Ewels, P., Magnusson, M., Lundin, S., & Käller, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw354 · Cited by 10,143
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090
Self-citationTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226
Robust rank aggregation for gene list integration and meta-analysis
Kolde, R., Laur, S., Adler, P., & Vilo, J. (2012) · Bioinformatics · doi:10.1093/bioinformatics/btr709 · Cited by 1,191
Jonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M., & Berns, A. (2001) · Nature Genetics · doi:10.1038/ng747 · Cited by 1,053
Self-citationResistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Self-citationReplication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930
Self-citationFollenzi, A., Ailles, L. E., Bakovic, S., Geuna, M., & Naldini, L. (2000) · Nature Genetics · doi:10.1038/76095 · Cited by 927
Poly(ADP-ribosyl)ation by PARP-1: `PAR-laying' NAD+ into a nuclear signal
Kim, M. Y., Zhang, T., & Kraus, W. L. (2005) · Genes & Development · doi:10.1101/gad.1331805 · Cited by 802
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756
Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells
Zellweger, R., Dalcher, D., Mutreja, K., Berti, M., Schmid, J. A., Herrador, R., Vindigni, A., & Lopes, M. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201406099 · Cited by 677
Self-citationREV7 counteracts DNA double-strand break resection and affects PARP inhibition
Xu, G., Chapman, J. R., Brandsma, I., Yuan, J., Mistrik, M., Bouwman, P., Bartkova, J., Gogola, E., Warmerdam, D., Barazas, M., et al. (2015) · Nature · doi:10.1038/nature14328 · Cited by 593
Self-citationScheinin, I., Sie, D., Bengtsson, H., van de Wiel, M. A., Olshen, A. B., van Thuijl, H. F., van Essen, H. F., Eijk, P. P., Rustenburg, F., Meijer, G. A., et al. (2014) · Genome Research · doi:10.1101/gr.175141.114 · Cited by 518
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514
Self-citationReplication fork reversal in eukaryotes: from dead end to dynamic response
Neelsen, K. J., & Lopes, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3935 · Cited by 508
Self-citationTopoisomerase I poisoning results in PARP-mediated replication fork reversal
Ray Chaudhuri, A., Hashimoto, Y., Herrador, R., Neelsen, K. J., Fachinetti, D., Bermejo, R., Cocito, A., Costanzo, V., & Lopes, M. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2258 · Cited by 499
Self-citationBreak-Induced Replication Repair of Damaged Forks Induces Genomic Duplications in Human Cells
Costantino, L., Sotiriou, S. K., Rantala, J. K., Magin, S., Mladenov, E., Helleday, T., Haber, J. E., Iliakis, G., Kallioniemi, O. P., & Halazonetis, T. D. (2014) · Science · doi:10.1126/science.1243211 · Cited by 461
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457
Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition
Berti, M., Ray Chaudhuri, A., Thangavel, S., Gomathinayagam, S., Kenig, S., Vujanovic, M., Odreman, F., Glatter, T., Graziano, S., Mendoza-Maldonado, R., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2501 · Cited by 452
Self-citationMeasuring error rates in genomic perturbation screens: gold standards for human functional genomics
Hart, T., Brown, K. R., Sircoulomb, F., Rottapel, R., & Moffat, J. (2014) · Molecular Systems Biology · doi:10.15252/msb.20145216 · Cited by 398
Koh, D. W., Lawler, A. M., Poitras, M. F., Sasaki, M., Wattler, S., Nehls, M. C., Stöger, T., Poirier, G. G., Dawson, V. L., & Dawson, T. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406182101 · Cited by 339
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P. W. B., Holstege, H., Liu, X., van Drunen, E., Beverloo, H. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4953 · Cited by 335
Self-citationRottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 304
Self-citationMurai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 293
Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
Dietlein, F., Thelen, L., & Reinhardt, H. C. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.06.003 · Cited by 280
Luijsterburg, M. S., de Krijger, I., Wiegant, W. W., Shah, R. G., Smeenk, G., de Groot, A. J. L., Pines, A., Vertegaal, A. C. O., Jacobs, J. J. L., Shah, G. M., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.01.019 · Cited by 275
Self-citationPARP inhibitor combination therapy
Dréan, A., Lord, C. J., & Ashworth, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.10.010 · Cited by 212
PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
Sugimura, K., Takebayashi, S.-I., Taguchi, H., Takeda, S., & Okumura, K. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200806068 · Cited by 211
XRCC1 and DNA polymerase β in cellular protection against cytotoxic DNA single-strand breaks
Horton, J. K., Watson, M., Stefanick, D. F., Shaughnessy, D. T., Taylor, J. A., & Wilson, S. H. (2008) · Cell Research · doi:10.1038/cr.2008.7 · Cited by 198
Pettitt, S. J., Rehman, F. L., Bajrami, I., Brough, R., Wallberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061520 · Cited by 172
PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs
Prahallad, A., Heynen, G. J. J. E., Germano, G., Willems, S. M., Evers, B., Vecchione, L., Gambino, V., Lieftink, C., Beijersbergen, R. L., Di Nicolantonio, F., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.037 · Cited by 168
Barazas, M., Annunziato, S., Pettitt, S. J., de Krijger, I., Ghezraoui, H., Roobol, S. J., Lutz, C., Frankum, J. R., Song, F., Brough, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.046 · Cited by 160
Self-citationPARPs and the DNA damage response
Sousa, F. G., Matuo, R., Soares, D. G., Escargueil, A. E., Henriques, J. A. P., Larsen, A. K., & Saffi, J. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs132 · Cited by 158
BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance
Duarte, A. A., Gogola, E., Sachs, N., Barazas, M., Annunziato, S., de Ruiter, J. R., Velds, A., Blatter, S., Houthuijzen, J. M., van de Ven, M., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4535 · Cited by 152
Self-citationJames, D. I., Smith, K. M., Jordan, A. M., Fairweather, E. E., Griffiths, L. A., Hamilton, N. S., Hitchin, J. R., Hutton, C. P., Jones, S. D., Kelly, P. J., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00609 · Cited by 143
Self-citationAng, J. E., Gourley, C., Powell, C. B., High, H. A., Shapira‐Frommer, R., Castonguay, V., Grève, J. D., Atkinson, T., Yap, T. A., Sandhu, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1262 · Cited by 141
Radiation-induced mitotic catastrophe in PARG-deficient cells
Amé, J., Fouquerel, E., Gauthier, L., Biard, D. S. F., Boussin, F. D., Dantzer, F., de MURCIA, G., & Schreiber, V. (2009) · Journal of Cell Science · doi:10.1242/jcs.039115 · Cited by 139
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
Ohmoto, A., & Yachida, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139336 · Cited by 139
Yan, Q., Xu, R., Zhu, L., Cheng, X., Wang, Z., Manis, J. P., & Shipp, M. A. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00990-12 · Cited by 138
The rise and fall of poly(ADP-ribose): An enzymatic perspective
Pascal, J. M., & Ellenberger, T. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.04.008 · Cited by 121
Lorenzo, S. B. D., Patel, A. G., Hurley, R. M., & Kaufmann, S. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00228 · Cited by 117
XRCC1 interactions with base excision repair DNA intermediates
Nazarkina, Z. K., Khodyreva, S. N., Marsin, S., et al. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.10.002 · Cited by 99
Gravells, P., Grant, E. K., Smith, K. M., James, D. I., & Bryant, H. E. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.02.010 · Cited by 97
Self-citationO’Connor, L. O., Rulten, S. L., Cranston, A. N., Odedra, R., Brown, H., Jaspers, J. E., Jones, L., Knights, C., Evers, B., Ting, A. K. T., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3240 · Cited by 96
Self-citationInhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells
Fathers, C., Drayton, R. M., Solovieva, S. E., & Bryant, H. E. (2012) · Cell Cycle · doi:10.4161/cc.11.5.19482 · Cited by 94
Moudrý, P., Watanabe, K., Wolanin, K., Bártková, J., Wassing, I. E., Watanabe, S., Strauss, R., Pedersen, R. T., Oestergaard, V. H., Lisby, M., et al. (2016) · The Journal of Cell Biology · doi:10.1083/jcb.201507042 · Cited by 92
BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
Kan, C. E., & Zhang, J. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.05.037 · Cited by 60
Kim, I.-K., Stegeman, R. A., Brosey, C. A., & Ellenberger, T. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624718 · Cited by 57
Cabezón, T., Gromova, I., Gromov, P., Serizawa, R., Wielenga, V. T., Kroman, N. T., Celis, J. E., & Moreira, J. M. A. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.019786 · Cited by 52
Self-citationPARP and PARG Inhibitors—New Therapeutic Targets in Cancer Treatment
Fauzee, N. J. S., Pan, J., & Wang, Y. (2010) · Pathology & Oncology Research · doi:10.1007/s12253-010-9266-6 · Cited by 46
Gromova, I., Gromov, P., Honma, N., Kumar, S., Rimm, D. L., Talman, M., Wielenga, V. T., & Moreira, J. M. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.05.003 · Cited by 39
Self-citationPARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency
Noll, A., Illuzzi, G., Amé, J., Dantzer, F., & Schreiber, V. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0333-2 · Cited by 31
PARP Inhibitors for Cancer Therapy
Curtin, N. J., & Sharma, R. A. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0 · Cited by 21
Annunziato, S., Barazas, M., Rottenberg, S., & Jonkers, J. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030924 · Cited by 13
Self-citationPARP Inhibitor Resistance—What Is Beyond BRCA1 or BRCA2 Restoration?
Xu, G., Jonkers, J., & Rottenberg, S. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0_19 · Cited by 1
Self-citation
Cited by
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Targeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 836
Self-citationA decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Metadata
- Authors
- Gogola, E., Duarte, A. A., de Ruiter, J. R., Wiegant, W. W., Schmid, J. A., de Bruijn, R., James, D. I., Guerrero Llobet, S., Vis, D. J., Annunziato, S., van den Broek, B., Barazas, M., Kersbergen, A., van de Ven, M., Tarsounas, M., Ogilvie, D. J., van Vugt, M., Wessels, L. F. A., Bartkova, J., Gromova, I., Andújar-Sánchez, M., Bartek, J., Lopes, M., van Attikum, H., Borst, P., Jonkers, J., & Rottenberg, S.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 33
- Issue
- 6
- Pages
- 1078-1093.e12
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2808113406
- Cited by
- 374
- References
- 75
- FWCI
- 13.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.